
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. shows a strong financial outlook, highlighted by a significant increase in gross revenue, which grew from $77.4K in 4Q23 to $194K in 2Q25, primarily attributed to improved coverage and an expanded prescriber base. The company's sales infrastructure has been successfully established, featuring 300 dedicated sales representatives and coverage that reaches 83% of all lives and 73% of commercial lives, fostering sustained revenue growth. Furthermore, the increase in new prescriptions (NRx) and total prescriptions (TRx), with NRx growing by 19% quarter-over-quarter in 2Q25, indicates strong patient retention and growing market adoption, reinforcing Axsome's position in the CNS therapy market.
Bears say
Axsome Therapeutics Inc has reported significant operating losses since its inception, indicating ongoing financial struggles that may impact future growth and investor confidence. Despite notable clinical results with AXS-12—demonstrating a 50% reduction in mean cataplexy attacks—this success may be overshadowed by the broader challenges faced by adults suffering from CNS disorders, including lower employment stability and reduced earnings. The company's reliance on developing therapies for CNS disorders with limited treatment options raises concerns about its financial sustainability and market viability as it continues to navigate operational deficits.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares